Clinical characteristics, risk factors, and incidence of symptomatic COVID-19 in adults living with HIV: a single-center, prospective observational study
Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, Martinez-Rebollar M, Laguno M, Callau P, Gonzalez-Navarro A, Leal L, Garcia F, Mallolas J, Mosquera M, Marcos MA, Ambrosioni J, Miro JM, Martinez E, Blanco JL; (on behalf the COVID-19 in HIV Investigators).
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models
Jewell BL, Mudimu E, Stover J, Ten Brink D, Phillips AN, Smith JA, Martin-Hughes R, Teng Y, Glaubius R, Mahiane SG, Bansi-Matharu L, Taramusi I, Chagoma N, Morrison M, Doherty M, Marsh K, Bershteyn A, Hallett TB, Kelly SL; HIV Modelling Consortium.
Conducting rapid qualitative research to support sex workers' health and social needs in the face of COVID-19: capitalising on stakeholder networks from the HIV response in Singapore to drive policymaking
Tan RKJ, Lim JM, Lo JJ, Teo AKJ, O'Hara CA, Ching AH, Ho V, Wong ML.
Economic, Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the COVID-19 Response on a Global Sample of Cisgender Gay Men and Other Men Who Have Sex with Men
Santos GM, Ackerman B, Rao A, Wallach S, Ayala G, Lamontage E, Garner A, Holloway IW, Arreola S, Silenzio V, Str√∂mdahl S, Yu L, Strong C, Adamson T, Yakusik A, Doan TT, Huang P, Cerasuolo D, Bishop A, Noori T, Pharris A, Aung M, Dara M, Chung SY, Hanley M, Baral S, Beyrer C, Howell S.
The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.
Musarrat F, Chouljenko V, Dahal A, Nabi R, Chouljenko T, Jois SD, Kousoulas KG.